<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81577</article-id><article-id pub-id-type="doi">10.7554/eLife.81577</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title><italic>PTPN22</italic> R620W gene editing in T cells enhances low avidity TCR responses</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-285048"><name><surname>Anderson</surname><given-names>Warren</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9315-5233</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285380"><name><surname>Barahmand-pour-Whitman</surname><given-names>Fariba</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167779"><name><surname>Linsley</surname><given-names>Peter S</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8960-4307</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241321"><name><surname>Cerosaletti</surname><given-names>Karen</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7403-6239</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241338"><name><surname>Buckner</surname><given-names>Jane H</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-285383"><name><surname>Rawlings</surname><given-names>David J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0810-1776</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Center for Immunity and Immunotherapies</institution>, <institution>Seattle Children's Research Institute</institution>, <addr-line><named-content content-type="city">Pittsboro</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution>Benaroya Research Institute</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Pediatrics</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-6021"><name><surname>Malissen</surname><given-names>Bernard</given-names></name><role>Reviewing editor</role><aff><institution>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université</institution>, <country>France</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>drawling@u.washington.edu</email> (DR);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e81577</elocation-id><history><date date-type="received"><day>04</day><month>07</month><year>2022</year></date><date date-type="accepted"><day>21</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Anderson et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Anderson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81577-v1.pdf"/><abstract><p>A genetic variant in the gene <italic>PTPN22 </italic>(R620W, rs2476601) is strongly associated with increased risk for multiple autoimmune diseases and linked to altered TCR regulation and T cell activation. Here, we utilize Crispr/Cas9 gene editing with donor DNA repair templates in human cord blood-derived, naive T cells to generate <italic>PTPN22</italic> risk edited (620W), non-risk edited (620R) or knock out T cells from the same donor. <italic>PTPN22</italic> risk edited cells exhibited increased activation marker expression following non-specific TCR engagement, findings that mimicked <italic>PTPN22</italic> KO cells. Next, using lentiviral delivery of T1D patient-derived TCRs against the pancreatic autoantigen, islet-specific glucose-6 phosphatase catalytic subunit-related protein (IGRP), we demonstrate that loss of PTPN22 function led to enhanced signaling in T cells expressing a lower avidity self-reactive TCR, but not a high avidity TCR. In this setting, loss of PTPN22 mediated enhanced proliferation and Th1 skewing. Importantly, expression of the risk variant in association with a lower avidity TCR also increased proliferation relative to <italic>PTPN22</italic> non-risk T cells. Together, these findings suggest that, in primary human T cells, <italic>PTPN22</italic> rs2476601 contributes to autoimmunity risk by permitting increased TCR signaling and activation in mildly self-reactive T cells, thereby potentially expanding the self-reactive T cell pool and skewing this population toward an inflammatory phenotype.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DP3DK111802</award-id><principal-award-recipient><name><surname>Anderson</surname><given-names>Warren</given-names></name><name><surname>Barahmand-pour-Whitman</surname><given-names>Fariba</given-names></name><name><surname>Linsley</surname><given-names>Peter S</given-names></name><name><surname>Cerosaletti</surname><given-names>Karen</given-names></name><name><surname>Buckner</surname><given-names>Jane H</given-names></name><name><surname>Rawlings</surname><given-names>David J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100018762</institution-id><institution>Seattle Children's Foundation</institution></institution-wrap></funding-source><award-id>Children's Guild Association Endowed Chair in Pediatric Immunology</award-id><principal-award-recipient><name><surname>Rawlings</surname><given-names>David J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009992</institution-id><institution>Seattle Children's Research Institute</institution></institution-wrap></funding-source><award-id>Center for Immunity and Immunotherapies</award-id><principal-award-recipient><name><surname>Rawlings</surname><given-names>David J</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009992</institution-id><institution>Seattle Children's Research Institute</institution></institution-wrap></funding-source><award-id>Program for Cell and Gene Therapy</award-id><principal-award-recipient><name><surname>Rawlings</surname><given-names>David J</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009992</institution-id><institution>Seattle Children's Research Institute</institution></institution-wrap></funding-source><award-id>Hansen Investigator in Pediatric Innovation Endowment</award-id><principal-award-recipient><name><surname>Rawlings</surname><given-names>David J</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Benaroya Family Gift Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rawlings</surname><given-names>David J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Study Approval (Human Subjects)For gene editing experiments using adult PBMCs, human donor leukopaks were purchased from the Fred Hutchinson Cancer Research Center, which were obtained from consenting donors under an IRB-approved protocol and cryopreserved. For gene editing experiments using umbilical cord blood derived PBMCs, cord units were purchased from the Bloodworks Northwest, which were obtained with consent under an IRB-approved protocol and cryopreserved. After collection, all samples were de-identified for the protection of human blood donors.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Prism files containing the numerical data and statistical tests used to generate all figures has been provided</p></sec><supplementary-material><ext-link xlink:href="elife-81577-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>